Trading under DCOY to commence on January 8, 2026Company’s proprietary peptide-conjugate platform leverages AI-enabled computational ...
InvestorsHub on MSN
Salarius shares jump after rebranding announcement to Decoy Therapeutics
Shares of Salarius Pharmaceuticals Inc (NASDAQ:SLRX) climbed 11.7% in premarket trading on Wednesday after the company said ...
Antibody-drug conjugates, a well-established antitumor strategy, are used for targeted delivery of cytotoxic drugs through antibodies. As cancer research progresses, other technologies with different ...
Peptide-drug conjugates (PDCs) are emerging as a promising alternative to antibody-drug conjugates (ADCs), offering enhanced tumor penetration and reduced immunogenicity. Carbonic anhydrase IX (CAIX) ...
Primary target patient population for the CBX-12 Phase 2 study is women with platinum-resistant or refractory ovarian cancer who are naïve to TOP1-targeted agents Study initiation follows positive ...
Bertozzi’s TwoStep Therapeutics to Target Solid Tumors With Engineered Peptide Drug Delivery Vehicle
Caitlyn Miller’s interest in cancer started when her stepfather was diagnosed with oral cancer when she was 10 years old. His diagnosis kicked off a 14-year battle that included different treatments ...
KAWASAKI, Japan--(BUSINESS WIRE)-- PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter “PeptiDream”) (Tokyo: 4587) today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback